Larimar Therapeutics, Inc. (LRMR) News
Follow Larimar Therapeutics, Inc. (LRMR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Larimar Therapeutics officer acquires $13,549 in common shares
Chief Development Officer Gopi Shankar acquired Larimar Therapeutics common shares worth $13,549.
EQUITY | Nov 12, 2026, 10:55 PM UTC
H
DELAYED UPDATE — Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Rese
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) NASDAQ:LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced tha
GEOPOLITICS | Nov 05, 2026, 09:09 PM UTC
L
Larimar appoints John B. Harlow, Jr. as President and COO
Larimar appointed John B. Harlow, Jr. as President and Chief Operating Officer, effective September 29, 2026.Original SEC Filing: Larimar Therapeutics, Inc. [ LRMR ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It
REGULATION | Sep 29, 2026, 08:13 PM UTC
L
Larimar Therapeutics, Inc. (LRMR) Appoints John Harlow as President and COO
Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective Sept. 29, 2026. An inducement grant includes options for 800,000 shares and 50,000 RSUs, vesting over four years.Material Det
EQUITY | Sep 29, 2026, 08:08 PM UTC
L
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) NASDAQ:LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced th
NEWS | Sep 29, 2026, 08:08 PM UTC
L
Larimar Therapeutics Appoints John Harlow as Pres and Oper Chief >LRMR
Larimar Therapeutics Appoints John Harlow as Pres and Oper Chief >LRMR
NEWS | Sep 29, 2026, 08:05 PM UTC
L
Larimar Therapeutics Price Target Announced at $13.00/Share by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 09:06 PM UTC
H
LRMR Seeks Accelerated Approval
LRMR submits first module for accelerated approval
EQUITY | Aug 04, 2026, 11:05 AM UTC
L
Larimar Therapeutics Reports Q2 2026 Results
Larimar Therapeutics releases Q2 financial update
EARNINGS | Aug 04, 2026, 11:00 AM UTC
L
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK CITY, NY / / July 5, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Larimar The
EQUITY | Jul 05, 2026, 02:00 PM UTC
L
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ: LRMR ) with a Buy rating and announces Price Target of $10.
EQUITY | Jul 02, 2026, 10:54 AM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
M
Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expect
Larimar Therapeutics submits first module of rolling BLA for accelerated approval of nomlabofusp.
REGULATION | Jun 29, 2026, 10:32 AM UTC